Vaxxel
Vaxxel is dedicated to developing innovative vaccines against respiratory infections, focusing on intranasal live attenuated multivalent vaccines for diseases like bronchiolitis and pneumonia. The company aims to address high burdens of disease in children and older adults with its advanced vaccine platforms and candidates.
Industries
Nr. of Employees
small (1-50)
Vaxxel
43 Boulevard du 11 Novembre 1918, Villeurbanne, 69100, Auvergne-Rhône-Alpes, France
Products
Bivalent intranasal live-attenuated RSV/HMPV vaccine candidate
A bivalent live-attenuated vaccine candidate designed for intranasal administration that expresses F proteins from respiratory syncytial virus and human metapneumovirus, demonstrated to be infectious and replicative in airway models and protective in animal challenge studies.
Bivalent intranasal live-attenuated RSV/HMPV vaccine candidate
A bivalent live-attenuated vaccine candidate designed for intranasal administration that expresses F proteins from respiratory syncytial virus and human metapneumovirus, demonstrated to be infectious and replicative in airway models and protective in animal challenge studies.
Services
Design and execution of preclinical efficacy and safety studies for intranasal live-attenuated respiratory vaccine candidates, including challenge models and immunogenicity assessment.
Cell-culture process development on Vero cell substrates and process optimization aimed at GMP-compliant production of live viral vaccines.
Design and execution of preclinical efficacy and safety studies for intranasal live-attenuated respiratory vaccine candidates, including challenge models and immunogenicity assessment.
Cell-culture process development on Vero cell substrates and process optimization aimed at GMP-compliant production of live viral vaccines.
Expertise Areas
- Live-attenuated vaccine development
- Intranasal vaccine delivery and mucosal immunology
- Preclinical efficacy and safety assessment
- Viral vector engineering and reverse genetics
Key Technologies
- Reverse genetics for RNA viruses
- Live-attenuated viral vaccine design
- Intranasal delivery platforms
- Human airway epithelium infection models
News & Updates
Vaxxel will present the latest development of its vaccine candidate during a session on 30 October 2024. Contact admin@vaxxel.fr for meetings.
Vaxxel announced positive preclinical efficacy results for its intranasal vaccine candidate against Pneumovirus infections, as detailed in a press release.
Vaxxel's recent research on its intranasal vaccine candidate against HMPV and RSV has been published in npj Vaccines, demonstrating promising efficacy.
Metavac® RSV-HMPV preclinical proof of concept achieved
Vaxxel has demonstrated preclinical proof of concept for its intranasal bivalent vaccine candidate targeting RSV and HMPV, showing protection in in vivo models.
The company secured funding to prepare for clinical trials of its respiratory vaccines, as reported by Les Echos.
Vaxxel will present the latest development of its vaccine candidate during a session on 30 October 2024. Contact admin@vaxxel.fr for meetings.
Vaxxel announced positive preclinical efficacy results for its intranasal vaccine candidate against Pneumovirus infections, as detailed in a press release.
Vaxxel's recent research on its intranasal vaccine candidate against HMPV and RSV has been published in npj Vaccines, demonstrating promising efficacy.
Metavac® RSV-HMPV preclinical proof of concept achieved
Vaxxel has demonstrated preclinical proof of concept for its intranasal bivalent vaccine candidate targeting RSV and HMPV, showing protection in in vivo models.
The company secured funding to prepare for clinical trials of its respiratory vaccines, as reported by Les Echos.